Thomas Shrader
Stock Analyst at BTIG
(2.23)
# 2,801
Out of 5,058 analysts
65
Total ratings
43.1%
Success rate
-1.85%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Reiterates: Buy | $16 | $9.46 | +69.13% | 5 | Nov 18, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $27 | $15.54 | +73.75% | 1 | Nov 17, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $15 → $16 | $5.79 | +176.34% | 3 | Nov 13, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $85 | $48.63 | +74.79% | 5 | Nov 10, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $9 | $4.86 | +85.19% | 2 | Nov 10, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $28.48 | +36.94% | 2 | Nov 5, 2025 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $3.12 | +156.41% | 3 | Nov 4, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $48 → $23 | $6.04 | +280.79% | 2 | Oct 22, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.22 | - | 4 | Oct 22, 2025 | |
| GANX Gain Therapeutics | Reiterates: Buy | $9 | $2.75 | +227.27% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $5.25 | +166.67% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $39.60 | +59.09% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $58.29 | +23.52% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.51 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.28 | +212.50% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.76 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.42 | +1,826.32% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $4.82 | +1,144.81% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $4.06 | +72.41% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $1.16 | +1,020.69% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.55 | +1,319.35% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.50 | +3,300.00% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.15 | +123.78% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.16 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.92 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.08 | +177.78% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $167.93 | +106.04% | 3 | Feb 21, 2019 |
Biohaven
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $9.46
Upside: +69.13%
Alto Neuroscience
Nov 17, 2025
Initiates: Buy
Price Target: $27
Current: $15.54
Upside: +73.75%
Coya Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $5.79
Upside: +176.34%
Vaxcyte
Nov 10, 2025
Reiterates: Buy
Price Target: $85
Current: $48.63
Upside: +74.79%
Aldeyra Therapeutics
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $4.86
Upside: +85.19%
Stoke Therapeutics
Nov 5, 2025
Reiterates: Buy
Price Target: $39
Current: $28.48
Upside: +36.94%
AC Immune
Nov 4, 2025
Reiterates: Buy
Price Target: $8
Current: $3.12
Upside: +156.41%
Arcturus Therapeutics Holdings
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $6.04
Upside: +280.79%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Gain Therapeutics
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $2.75
Upside: +227.27%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $5.25
Upside: +166.67%
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $39.60
Upside: +59.09%
Sep 8, 2025
Initiates: Buy
Price Target: $72
Current: $58.29
Upside: +23.52%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.51
Upside: -
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.28
Upside: +212.50%
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.76
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.42
Upside: +1,826.32%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.82
Upside: +1,144.81%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $4.06
Upside: +72.41%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $1.16
Upside: +1,020.69%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.55
Upside: +1,319.35%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.50
Upside: +3,300.00%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $7.15
Upside: +123.78%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.16
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.92
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.08
Upside: +177.78%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $167.93
Upside: +106.04%